Compare Hut 8 Corp (HUT) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Natera Inc. Common Stock — how do they compare? Hut 8 Corp trades at $72.8 (market cap $10.31B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 5.5× Hut 8 Corp's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 12 Days and Natera Inc. Common Stock for 0 Days on average.
| HUT | NTRA | |
|---|---|---|
Market Cap | $10.31B | $57.03B |
Volume | 4,904,746 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $133.02 | $425.64 |
52-Week Low | $33.76 | $179.42 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $17.74B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $83.61, down 1.91% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth projections but faces significant profitability challenges with a -188.59% net income margin. Recent developments include securing a $1.07 billion credit facility and positive analyst coverage with 94% buy ratings and a $163.62 consensus price target.
While analyst sentiment remains overwhelmingly positive, HUT faces substantial execution risks with consecutive earnings misses and negative cash flow from operations. The stock offers significant upside potential based on analyst targets but requires careful monitoring of profitability improvements and AI infrastructure contract execution.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
